BOSTON, Sept. 23 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today
announced that its Chief Executive Officer, Thomas J. Bigger, will present an
overview of the company's strategy and research programs at the UBS Global
Life Sciences Conference in New York next week. Details of the presentation
Date: Wednesday, September 29, 2004
Time: 4:00 p.m. (EDT)
Location: The Grand Hyatt New York, Ballroom E
Speaker: Thomas J. Bigger, Chief Executive Officer
Audio Webcast: Available for 30 days on the Investor Relations page at
Mr. Bigger's presentation will review Paratek's Tetracycline ("TET") and
Multiple Adaptational Response ("MAR") Programs, as well as the company's most
recent efforts to exploit its compounds and their unique mechanisms of action
in selected anti-inflammatory and neurodegenerative conditions including
A copy of the Paratek presentation will be available upon request.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek's lead programs are advancing novel compounds
that can circumvent or block bacterial resistance, as well as drugs that can
prevent infection by many gram-negative bacteria by interfering with Multiple
Adaptational Response (MAR) mechanisms in bacteria. Out of these efforts,
Paratek has discovered a new class of antibiotics, the aminomethylcyclines
that target the need for new and potent antibacterials to overcome the problem
of rapidly growing bacterial resistance. The Company's lead antibiotic
clinical candidate, BAY 73-7388, the first product from this class, is being
developed in a collaborative partnership with Bayer HealthCare AG.
Paratek is privately held and headquartered in Boston, Massachusetts, USA.
For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.